Dr Reddys

Mumbai, Nov 29 (UNI) Pharma major Dr Reddys Laboratories today announced that they have inked a pact with Torrent Pharmaceuticals for exclusive commercialization of two of Torrent's brands, Listril (Lisinopril) and Listril Plus (Lisinopril HCTZ), in Russia.

Both Listril and Listril Plus are cardiovascular drugs used for the treatment of high blood pressure.

Informing the Bombay Stock Exchange (BSE), Dr Reddys said the two brands would add to the stable of cardiovascular drugs the company is currently offering in Russia. This agreement offers good potential for immediate commercialization of these two brands as they have already been registered in Russia.

It may be recalled that this is the second agreement of this kind Dr Reddys has made with Torrent Pharma for the territory of Russia.

The first was related to the licensing for Omez D, which is used to treat gastro-intestinal diseases like heartburn, dyspepsia and epigastric pain.

Listril will be launched first in Ukraine and Kazakhstan and then in Russia and Belarus.

UNI SN WD AW1622